PD-1 antibody nivolumab monotherapy did not present any advantage in the improvement of OS or progression-free survival (PFS) as second-line treatment setting for relapsed SCLC according to the Checkmate 331 study (35). This evidence concerns the gene PDCD1 and small cell lung carcinoma.